Patients will be able to access Eli Lilly's weight loss drug Zepbound at Walmart pharmacies nationwide through its direct-to-consumer program as soon as next month.  The partnership between Eli Lilly and Company and Walmart, announced Wednesday, will allow people with a valid prescription to pick up single-dose vials of Zepbound at Walmart pharmacies nationwide or opt for home delivery. Both are enabled through Eli Lilly's direct-to-consumer platform, LillyDirect.  Lily's direct-to-consumer platform, which ...

Core Insights - Eli Lilly and Walmart have partnered to offer single-dose vials of the weight loss drug Zepbound at Walmart pharmacies, matching the price available through LillyDirect [1][2][3] - The service will be available at nearly 4,600 Walmart pharmacies across the U.S. by mid-November, allowing customers to select local pickup during the checkout process on LillyDirect [2][5] - This collaboration marks LillyDirect's first retail partnership and aims to enhance access to prescription medications for patients managing chronic diseases like obesity [3][4][6] Company and Industry Developments - The partnership is designed to provide additional convenience and choice for customers in obtaining their medications, addressing access challenges faced by patients [4][5] - LillyDirect, launched in January 2024, serves as a digital healthcare platform for patients with obesity, migraines, and diabetes, facilitating access to healthcare providers and home delivery of medications [6] - The trend towards consolidated online healthcare platforms is highlighted, indicating a shift in consumer preferences for streamlined healthcare management [7]

Cantor Fitzgerald reaffirms its "Overweight" rating for Eli Lilly (NYSE:LLY), increasing its price target from $825 to $925.Eli Lilly partners with HealthTap to enhance its digital healthcare platform, LillyDirect, focusing on virtual diabetes management services.The addition of Peter Marks, a former top vaccine regulator, to Eli Lilly's team is expected to bolster the company's pharmaceutical innovations.Eli Lilly (NYSE:LLY) is a leading pharmaceutical company known for its innovative treatments and therap ...

Core Insights - HealthTap is partnering with Eli Lilly to provide virtual diabetes management services through LillyDirect [1] Company Summary - HealthTap is a telehealth company that focuses on digital healthcare solutions [1] - Eli Lilly is expanding its digital healthcare platform, LillyDirect, to include diabetes management services [1] Industry Summary - The collaboration highlights the growing trend of integrating telehealth services into traditional healthcare frameworks, particularly for chronic disease management [1]

Core Viewpoint - Novo Nordisk is launching a direct-to-consumer online pharmacy, NovoCare, offering its weight loss drug Wegovy at a significantly reduced price of $499 per month, compared to its previous list price of nearly $1,350 per month, aiming to increase accessibility for patients without insurance coverage [1][3]. Group 1: Pricing and Accessibility - The new cash-pay offering is designed for millions of patients lacking insurance coverage, including those on Medicare, to make Wegovy more accessible [2]. - Wegovy will be available for $499 per month through NovoCare, which is less than half of its original list price [3]. - The pharmacy will provide home delivery of Wegovy prescriptions and additional patient support services, including refill reminders and access to live case managers [3][4]. Group 2: Competitive Landscape - Novo Nordisk's strategy mirrors that of its main competitor, Eli Lilly, which launched its own direct-to-consumer online pharmacy, LillyDirect, to facilitate access to its weight loss drug Zepbound [5]. - Eli Lilly's LillyDirect also offers Zepbound at a reduced price, with single-dose vials available for half or less of its usual $1,000 monthly list price [6]. - The FDA has recently declared the shortages of both Zepbound and Wegovy over, which will limit the ability of compounding pharmacies to create unapproved versions of these injections [6].